Clazosentan
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aneurysmal Subarachnoid Hemorrhage
Conditions
Aneurysmal Subarachnoid Hemorrhage
Trial Timeline
Mar 1, 2016 → May 2, 2017
NCT ID
NCT02560532About Clazosentan
Clazosentan is a phase 2 stage product being developed by Idorsia for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT02560532. Target conditions include Aneurysmal Subarachnoid Hemorrhage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02560532 | Phase 2 | Completed |
Competing Products
8 competing products in Aneurysmal Subarachnoid Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erythropoietin beta | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Phase 2 | 51 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 2 | 47 |
| GTX-104 + Nimodipine Capsules | Grace Therapeutics | Phase 1 | 25 |
| GTX-104 + Nimotop 30 MG Oral Capsule | Grace Therapeutics | Phase 3 | 69 |